EFFECTS OF KARMIZOLE DERIVATE ON THE EXPRESSION OF APO A-I GENE IN THE RAT’S HYPERLIPIDEMIA MODEL

Full Text

Introduction. Azoles are the main antifungal drug class. The main mechanism of the azoles action is the intercalation in the sterol biosynthesis regulation. Azole derivates interact with the SREBP transcription factor, repressing the sterol biosynthesis [1]. At the same time, the effect of the azole derivates on mammals is antiatherogenic. But there were no publication about connection between azole derivates effect on hyperlipidemia and expression of genes with antiatherogenic effects. One of such genes, that could be effected by azole derivates, is Apo A-I gene [2]. In our work we used triton model of hyperlipodemia on rats to analyze the effect of carmizole injection on the expression of the main antiatherogenic lipoprotein gene Apo A-I. Materials and methods. We had four groups of rats: intact control group, triton control group, phenophibrate group and carmizole group. During a seven days we gave a per oral injections of carmizole for the carmizole group, phenophibrate (as a comparison drug) for phenophibrate group and 1% starch solution for triton control group. On the seven day rats from these groups went through intraperitoneal injection of triton WR-1339 (48.5 mg/ml). On the next day all for groups went through decapitation. Liver tissue samples were taken from each rat. This tissue samples were used for RNA extraction and following RT-PCR (Real Time PCR) with primers for Apo A-I mRNA sequence. Results. We made Real-Time PCR with rat liver cDNA with primers for Apo A-I mRNA for all experimental groups. We have found, that Apo A-I mRNA level decreased in the triton control group to 17%, decreased in the phenophibrate group to 12%, but restored up to 89% in the carmizole group. Conclusions. Carmizole derivate drug works like stimulator of Apo A-I gene expression. That increasing of the expression of antiatherogenic protein gene could me the base of the antiatherogenic effect of the carmizole derivate.

About the authors

A V Lizunov

Department of Neuropharmacology, Institute of the Experimental Medicine, Saint Petersburg

I V Okunevich

Department of Neuropharmacology, Institute of the Experimental Medicine, Saint Petersburg

P D Shabanov

Department of Neuropharmacology, Institute of the Experimental Medicine, Saint Petersburg

References

Supplementary files